Refereed Publications
1993 1996 1997 1998 1999 2001 2002 2003 2004 2005
1. Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine (2'-NH2-MPTP): A comparative study with 2'-CH3-MPTP and MPTP. A. M. Andrews and D. L. Murphy, Journal of Neurochemistry 60:1167-1170 (1993) (ABSTRACT or PDF).
2.
2'-NH2-MPTP in Swiss Webster mice: Evidence for long term
(six month) depletions in cortical and hippocampal 5-HT and NE,
differential protection by selective uptake inhibitors or clorgyline,
and functional changes in central 5-HT neurotransmission. A. M. Andrews
and D. L. Murphy, Journal
of Pharmacology and Experimental
Therapeutics
267:1432-1439 (1993) (ABSTRACT or PDF).
3.
Fluoxetine and desipramine selectively
attenuate
2'-NH2-MPTP-induced depletions in serotonin and norepinephrine. A. M.
Andrews and D. L. Murphy, European
Journal of Pharmacology
250:215-221
(1993) (ABSTRACT or PDF).
4. Transgenic mice
with high levels of
superoxide dismutase
activity are protected from the neurotoxic effects of 2'-NH2-MPTP on
serotonergic and noradrenergic nerve terminals.
A. M. Andrews, B.
Ladenheim, C. J. Epstein, J. L. Cadet and D. L.
Murphy, Molecular
Pharmacology 50:1511-1519 (1996) (ABSTRACT or PDF).
5. Differential
reinforcing effects of
cocaine and GBR-12909:
Biochemical evidence for divergent neuroadaptive changes in the
mesolimbic dopaminergic system. S. R. Tella, B. Ladenheim, A. M.
Andrews, S. R. Goldberg and J. L. Cadet, Journal
of Neuroscience
16:7416-7427 (1996) (ABSTRACT or PDF).
6. Gene structure and 5'-flanking regulatory region of the murine serotonin transporter. D. Bengel, A. Heils, S. Petri, M. Seemann, K. Glatz, A. M. Andrews, D. L. Murphy and K. P. Lesch, Brain Research Molecular Brain Research 44:286-292 (1997) (ABSTRACT or PDF).
7. Cellular
localization and expression of
the serotonin
transporter in mouse brain. D. Bengel, O. Jöhren, A. M.
Andrews, A. Heils, R. Mößner, G. L.
Sanvitto, J. M.
Saavedra, K. P. Lesch and D. L.
Murphy, Brain Research 778:338-345
(1997) (ABSTRACT or PDF).
8. Altered brain
serotonin homeostasis and
locomotor
insensitivity to 3, 4- methylenedioxy-methamphetamine ("Ecstasy") in
serotonin transporter-deficient mice. D. Bengel, D. L.
Murphy, A.
M.
Andrews, C. H. Wichems, D. Feltner, A. Heils, R. Mossner, H.
Westphal
and K. P. Lesch, Molecular
Pharmacology 53:649-655
(1998) (ABSTRACT or PDF).
9. Brain serotonin
neurotransmission: An
overview and update
with an emphasis on serotonin subsystem heterogeneity, multiple
receptors, interactions with other neurotransmitter systems, and
consequent implications for understanding the actions of serotonergic
drugs.
D. L. Murphy, A. M. Andrews,
C. H. Wichems, Q. Li, M. Tohda
and
B. Greenberg, Journal of Clinical Psychiatry
59:4-12 (1998) (ABSTRACT or PDF).
10.
Delta opioid peptide [D-Ala2,D-leu5]enkephalin blocks the
long-term loss of dopamine transporters induced by multiple
administrations of methamphetamine: Involvement of opioid receptors and
reactive oxygen species. L. I. Tsao, B. Ladenheim, A. M. Andrews, C. C.
Chiueh, J. L. Cadet and T. P. Su, Journal
of Pharmacology and
Experimental Therapeutics 287:322-331 (1998) (ABSTRACT or PDF).
11. Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (Ecstasy). S. Jayanthi, B. Ladenheim, A. M. Andrews and J. L. Cadet, Neuroscience 91:1379-1387 (1999) (ABSTRACT or PDF).
12.
Molecular mechanisms of cocaine reward: Combined dopamine
and serotonin transporter knockouts eliminate cocaine place preference.
I. Sora, F. S. Hall, A. M. Andrews,
M. Itokawa, X. F. Li, H. B. Wei, C.
Wichems, K. P. Lesch, D. L.
Murphy and G. R. Uhl, Proceedings
of the
National Academy of Science USA 98:5300-5305 (2001)
(ABSTRACT or PDF).
13.
Genetic perspectives on the serotonin
transporter. D. L.
Murphy, Q. Li, S. Engel, C. Wichems,
A. M. Andrews, K. P. Lesch and G.
Uhl, Brain
Research Bulletin 56:487-494 (2001) (ABSTRACT or PDF).
14. GAP-43 is
critical for normal
development of the
serotonergic innervation in forebrain. S. L. Donovan, L. A. Mamounas,
A. M. Andrews, M. E. Blue and J. S. McCasland, Journal
of Neuroscience
22:3543-3552 (2002) (ABSTRACT or PDF).
15.
2'-NH2-MPTP
(1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine) depletes
serotonin and norepinephrine in rats: A comparison with 2'-CH3-MPTP
(1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine). E. L. Unger,
P. Mazzola-Pomietto, D. L.
Murphy and A. M. Andrews,
Journal
of
Pharmacology and Experimental Therapeutics 303:527-533 (2002)
(ABSTRACT or PDF).
16.
Neuronal and astroglial responses to the serotonin and
norepinephrine neurotoxin:
1-Methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine. B. A. Luellen,
D. B. Miller, A. C. Chisnell, D. L.
Murphy, J. P. O'Callaghan and A. M.
Andrews, Journal of Pharmacology and Experimental
Therapeutics
307:923-931 (2003) (ABSTRACT or PDF).
17. The role of
membrane and vesicular
monoamine transporters
in the neurotoxic and hypothermic effects of 2'-NH2-MPTP. A. L. Numis,
E. L. Unger,
D. L. Sheridan, A. C. Chisnell and A.
M. Andrews,
Molecular
Pharmacology, 66:718-727 (2004) (ABSTRACT or PDF).
18. Late onset loss
of hippocampal 5-HT and
NE is accompanied
by an increase in BDNF protein expression in mice co-expressing mutant
APP and PS1. M.
E. Szapacs, A.
L. Numis and A. M. Andrews,
Neurobiology
of Disease 16:572-580 (2004) (ABSTRACT or PDF).
19. Exploring the
relationship between
serotonin and brain
derived neurotrophic factor: Analysis of BDNF protein and extraneuronal
5-HT in mice with reduced serotonin transporter or BDNF expression. M.
E. Szapacs, T.
A. Mathews, L. Tessarollo, W. E. Lyons, L. A. Mamounas
and A. M. Andrews, Journal
of Neuroscience Methods
140:81-92 (2004) (ABSTRACT or PDF).
20. Gene
dose-dependent alterations in
extraneuronal serotonin
but not dopamine in mice with reduced serotonin transporter expression.
T. A. Mathews,
D. E. Fedele, F. M. Coppelli, A. L. Avila, D. L.
Murphy
and A. M. Andrews, Journal
of Neuroscience Methods
140:169-181 (2004) (ABSTRACT or PDF).
21.
Chronoamperometry detects differential changes in
synaptosomal uptake in serotonin transporter knockout mice. X. A. Perez
and A. M. Andrews, Analytical
Chemistry 77:818-826
(2005) (ABSTRACT or PDF) .
22.
Altered serotonin synthesis, turnover
and dynamic
regulation in multiple brain regions of mice lacking the serotonin
transporter. D. K. Kim, T. J. Tolliver, S. J. Huang, B. J.
Martin, A.
M. Andrews, C. Wichems, A. Holmes, K. P. Lesch, D. L.
Murphy,
Neuropharmacology,
49:798-810 (2005) (ABSTRACT or PDF).
23. Locomotor
hyperactivity and alterations
in dopamine
neurotransmission are associated with overexpression of A53T mutant
human ±-synuclein in mice. E. L. Unger, D. Eve, X. A. Perez,
D. K. Reichenbach, Y. Xu, M. K. Lee and
A. M. Andrews, Neurobiology
of
Disease, 21:431-443 (2006) (ABSTRACT or PDF).
24. The neurotoxin
2'-NH2-MPTP degenerates
serotonin axons and
evokes increases in hippocampal BDNF. B. A. Luellen, M. E. Szapacs,
C.
K. Materese and A. M.
Andrews, Neuropharmacology,
50:297-308 (2006) (ABSTRACT or PDF).
25.
Filtration compromises synaptosomal
membranes during
radiochemical assay of serotonin uptake: Comparison with
chronoamperometry in SERT knockout mice. X. A. Perez, L. E. Bianco and
A. M. Andrews, Journal
of Neuroscience Methods,
154:245-255 (2006) (ABSTRACT or PDF).
26. Radical-induced degradation of liposome-encapsulated microtubules as a model of axonal damage due to oxidative stress. A. E. Counterman, T. G. D'Onofrio, A. M. Andrews and P. S. Weiss, Proceedings of the National Academy of Sciences, USA, 103:5262-5266 (2006) (ABSTRACT or PDF).
27. Microcontact insertion printing. T. J. Mullen, C. Srinivasan, J. N. Hohman, S. D. Gillmor, M. J. Shuster, M. W. Horn, A. M. Andrews and P. S. Weiss, Applied Physics Letters, 90:063114-063117 (2007) (ABSTRACT or PDF).
28. Reduced BDNF is associated with a loss of serotonergic innervation in the hippocampus of aging mice. B. A. Luellen, L. E. Bianco, L. M. Schneider and A. M. Andrews, Genes, Brain and Behavior, 6:482-490 (2007). (ABSTRACT or copies of PDF can be requested directly from ama11[at]psu.edu).
29. Scanning electron microscopy of nanoscale chemical patterns. C. Srinivasan, T. J. Mullen, J. N. Hohman, M. E. Anderson, A. A. Dameron, A. M. Andrews, E. C. Dickey, M. W. Horn, P. S. Weiss, ACS Nano, 1:191-201 (2007). (ABSTRACT or PDF)
30. Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperseotonergic phenotype. B. P. Guiard, D. L. David, T. Deltheil, F. Chenu, E.L. Maitre, T. Renoir, I. Lerous-Nicollet, P. Sokoloff, L. Landumey, M. Hamon, A. M. Andrews, R. Hen and A. M. Gardier, International Journal of Neuropsychophamracology, Jun 11:1-14 (2007). (ABSTRACT or PDF)
31. Biospecific recognition of tethered small molecules diluted in self-assembled monolayers. M. J. Shuster, A. Vaish, M. E. Szapacs, M. E. Anderson, P. S. Weiss and A. M. Andrews, Advanced Materials, 20:164-167 (2008). (ABSTRACT or PDF)
2. Determining serotonin and dopamine uptake rates using high-speed chronoamperometry. X. A. Perez, A. J. Bressler and A. M. Andrews, in Electrochemical Methods for Neuroscience. A. C. Michael and L. A. Borland, eds., CRC Press LLC, Boca Raton, FL: 103-124(2007). (LINK)
3. Selecting and driving monolayer structures through tailored intermolecular interactions. T. J. Mullen, A. A. Dameron, A. M. Andrews and P. S. Weiss, Aldrichimica Acta, 40:21-31 (2007) (ABSTRACT or PDF).
4. A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. M. A. Fox, A. M. Andrews, J. R. Wendland, K. P. Lesch, A. Holmes and D. L. Murphy, Psychopharmacology, 195(2):147-66 (2007) (ABSTRACT OR PDF).
1. Microdialysis study of the effects of genetic inactivation of the serotonin transporter gene on baseline and K+-stimulated extracellular serotonin concentrations in mouse striatum. D. E. Fedele and A. M. Andrews, in Monitoring Molecules in Neuroscience. Proceedings of the 8th International Conference on In Vivo Methods. H. Rollema, E. Abercrombie, D. Sulzer and J. Zackheim, eds., The State University of New York, Stony Brook, NY: 193-194 (1999).
2.
Quantitative microdialysis for serotonin in striatum and
frontal cortex of genetically altered mice. D. E. Fedele, T. A.
Mathews, L. A. Mamounas, W. E. Lyons and A. M. Andrews, in Monitoring
Molecules in Neuroscience. Proceedings of the 9th International
Conference on In Vivo Methods. W. T. O'Connor, J. P. Lowry,
J. J.
O'Connor and R. D. O'Neill, eds., University College, Dublin Ireland:
97-98. (2001).
3.
SERT as a key regulator of serotonergic signaling and the
effects on anxiety-related behavior. T. A. Mathews, X. A. Perez, E. L.
Unger, M. E. Szapacs, B. A. Luellen and
A. M. Andrews, in Monitoring
Molecules in Neuroscience. Proceedings of the 10th International
Conference on In Vivo Methods. J. Kehr, K. Fuxe, U. Ungerstedt and T.
Svensson eds., Karolinska Institutet, Stockholm, Sweden: 383-385 (2003).
4.
MDMA-induced dopamine and serotonin release does not
stimulate locomotor activity in SERT knockout mice: importance of
5-HT1B receptors. T. A. Mathews, E. L. Unger, D. E. Fedele, K. P.
Lesch,
D. L. Murphy and A. M.
Andrews, in Monitoring Molecules in
Neuroscience. Proceedings of the 11th International Conference on In
Vivo Methods. V. Valentini and G. Di Chiara eds., University of
Cagliari, Sardinia, Italy (in press).
